Core Viewpoint - Dyadic International, Inc. is set to report its financial results for the second quarter of 2025 and will host a corporate update conference call on August 13, 2025 [1] Group 1: Financial Reporting - The company will announce its financial results for Q2 2025 on August 13, 2025 [1] - A conference call will take place at 5:00 p.m. Eastern Time on the same day [2] - Dial-in numbers for the conference call are provided, including a toll-free option and an international number [2] Group 2: Company Overview - Dyadic is a global biotechnology company focused on scalable production of high-value, precision-engineered functional input proteins [1][4] - The company utilizes proprietary gene expression platforms for applications in life sciences, food and nutrition, and industrial biotechnology [1][4] - Dyadic's C1 and Dapibus™ expression systems support flexible and cost-effective manufacturing, forming the basis of its commercial and partnered programs [4]

Core Insights - Dyadic International, Inc. reported significant progress in commercializing its proprietary Dapibus™ and C1 microbial protein production platforms, aiming for long-term growth opportunities in life sciences, nutrition, and industrial applications [1][2]. Company Developments - The company is focusing on developing scalable products with recurring revenue potential, supported by partnerships with organizations like CEPI and the Gates Foundation [2]. - Dyadic has expanded its life science and industrial portfolio with six additional products in development, including non-animal cell culture media and various enzymes [3][4]. - A research grant of up to $4.5 million was awarded from CEPI, and a $3 million project with the Gates Foundation is underway for malaria and RSV antibody programs [4][12]. Financial Highlights - As of March 31, 2025, the company reported cash, cash equivalents, and investment-grade securities of approximately $7.4 million, down from $9.3 million at the end of 2024 [15]. - Revenue for Q1 2025 increased to approximately $394,000, up from $335,000 in the same period last year, driven by grant revenue [16]. - The cost of revenue increased to approximately $298,000 compared to $144,000 a year ago, reflecting a rise in collaborations [17]. - Research and development expenses decreased to $495,000 from $523,000 year-over-year, indicating a reduction in ongoing internal projects [18]. - General and administrative expenses decreased by 10.8% to $1,596,000 compared to $1,789,000 in the previous year [19]. - The net loss for Q1 2025 was $2,028,000, slightly higher than the $2,010,000 loss in the same period last year [23]. Product Development - Dyadic is progressing towards a commercial launch of Human Serum Albumin in Q3 2025, with anticipated milestone payments related to productivity improvements [5]. - The company is also developing recombinant transferrin and fibroblast growth factor (FGF) for various applications, showing comparable performance to reference standards in initial studies [5][11]. - The C1 platform is being advanced through a $4.5 million CEPI grant to accelerate recombinant protein vaccine development [12]. Market Position - Dyadic's proprietary microbial protein production platforms are positioned to drive revenue growth in high-value life sciences and industrial markets, with a focus on affordable biologics and proteins [2][26]. - The company is actively engaging partners for its recombinant products, including non-animal alternatives for research and commercial bioprocessing applications [5][11].